The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) represent the standard of care as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harbouring EGFR mutation. There are few treatment options after progression from TKI. In the absence of targetable mutations, patients who develop resistance are usually treated with chemotherapy. There are limited data focusing the role of TKI re-treatment. We present the case of a patient who achieved clinical benefit and objective response upon re-treatment with a first-generation anti-EGFR TKI.

Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient. A case report / Galletti, Alessandro; Russano, Marco; Citarella, Fabrizio; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele. - In: PRECISION CANCER MEDICINE. - ISSN 2617-2216. - 3:December(2020), pp. 29-29. [10.21037/pcm-20-56]

Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient. A case report

Santini, Daniele
2020

Abstract

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) represent the standard of care as first-line treatment for patients with non-small-cell lung cancer (NSCLC) harbouring EGFR mutation. There are few treatment options after progression from TKI. In the absence of targetable mutations, patients who develop resistance are usually treated with chemotherapy. There are limited data focusing the role of TKI re-treatment. We present the case of a patient who achieved clinical benefit and objective response upon re-treatment with a first-generation anti-EGFR TKI.
2020
non-small-cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); target therapy; tyrosine kinase inhibitors (TKI)
01 Pubblicazione su rivista::01i Case report
Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient. A case report / Galletti, Alessandro; Russano, Marco; Citarella, Fabrizio; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele. - In: PRECISION CANCER MEDICINE. - ISSN 2617-2216. - 3:December(2020), pp. 29-29. [10.21037/pcm-20-56]
File allegati a questo prodotto
File Dimensione Formato  
Galletti_Effective_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 275.15 kB
Formato Adobe PDF
275.15 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1705051
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact